Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Пациент с артериальной гипертензией и очень высоким риском развития осложнений: роль тройной фиксированной комбинации лекарственных препаратов - Научно-практический журнал Cardioсоматика Том 9, №4 (2018)
Пациент с артериальной гипертензией и очень высоким риском развития осложнений: роль тройной фиксированной комбинации лекарственных препаратов
Ларина В.Н., Орлов Д.А. Пациент с артериальной гипертензией и очень высоким риском развития осложнений: роль тройной фиксированной комбинации лекарственных препаратов. CardioСоматика. 2018; 9 (4): 17–25. DOI: 10.26442/22217185.2018.4.180075
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье представлено клиническое наблюдение пациента среднего возраста с неконтролируемой артериальной гипертензией и очень высоким сердечно-сосудистым риском. Коррекция терапии в виде добавления фиксированной комбинации ингибитора ангиотензинпревращающего фермента, блокатора медленных кальциевых каналов и диуретика в максимальных дозах способствовала снижению уровней офисного систолического артериального давления (САД) и диастолического (ДАД) на 24 и 16% соответственно, CАД и ДАД по данным суточного мониторирования АД – на 16%, индекса времени САД на 17,1%, ДАД – на 37,4% и вариабельности САД и ДАД на 18 и 30% соответственно, а также улучшению приверженности лечению.
Ключевые слова: артериальная гипертензия, фиксированная комбинация, сердечно-сосудистый риск.
Key words: arterial hypertension, fixed combination, cardiovascular risk.
Ключевые слова: артериальная гипертензия, фиксированная комбинация, сердечно-сосудистый риск.
________________________________________________
Key words: arterial hypertension, fixed combination, cardiovascular risk.
Полный текст
Список литературы
1. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
2. Чазова И.Е. Артериальная гипертония в свете современных рекомендаций. Терапевтический архив. 2018; 90 (9): 4–7. / Chazova I.E. Arterial'naia gipertoniia v svete sovremennykh rekomendatsii. Therapeutic Archive. 2018; 90 (9): 4–7. [in Russian]
3. Forouzanfar M, Liu P, Roth G et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017; 317: 165–82.
4. Меna LJ, Maestre GE, Hansen TW et al. The behalf of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information? Am J Hypertens 2014; 27 (1): 46–55.
5. Mancia G, Fagard R et al. ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014; 23: 3–16.
6. Williams B, Mancia G, Spiering W et al. ESC Scientific Document Group; 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J 2018; 39 (33): 3021–104.
7. Pall D, Szanto L, Szabo Z. Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of treatment with Perindopril, Amlodipine, and Indapamide SR. Clin Drug Investig 2014; 34 (10): 701–8.
8. Остроумова О.Д., Кочетков А.И., Павлеева Е.Е., Гусева Т.Ф. Современные представления о выборе фиксированных комбинаций антигипертензивных препаратов: фокус на эффективность и прогноз. Лечебное дело. 2018; 2: 39–48. / Ostroumova O.D., Kochetkov A.I., Pavleeva E.E., Guseva T.F. Sovremennye predstavleniia o vybore fiksirovannykh kombinatsii antigipertenzivnykh preparatov: fokus na effektivnost' i prognoz. Lechebnoe delo. 2018; 2: 39–48. [in Russian]
9. Morisky DE, Ang A, Krousel-Wood M, Harry J. Ward. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10 (5): 348–54.
10. Ferreire SA. bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 1965; 24:163–9.
11. Gavras H, Brunner HR, Turini GA et al. Antihypertensive effect of the oral angiotensin convertingenzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298 (18): 991–5.
12. Yang L, Zhang J, Li N et al. Bradykinin receptor in immune-mediated renal tubular injury in trichloroethylene-sensitized mice: Impact on NF-kB signaling pathway. J Immunotoxicol 2018; 15 (1): 126–36.
13. Yousif M, Benter I, Diz D, Chappell M. Angiotensin-(1-7)-dependent vasorelaxation of the renal arteryexhibitsunique angiotensin and bradikinin receptor selektivity. Peptides 2017; 90: 10–6.
14. Gouni-Berthoid Hanssen R, Ravarani L, Berthold H. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. Curr Pharm Des 2017; 23 (31): 4573–82.
15. Jicheng L, Jicheng L, Perkovic V, Foote CV. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012; 12: CD004136.
16. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033–41.
17. Fox K, Henderson J, Bertrand M et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.
18. Dahlof B, Sever P, Poulter N et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
19. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166 (6): 659–66.
20. Parati G, Dolan E, Schumacher H. Impact of antihypertensive combination and monotreatments on blood pressure variability: assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database. J Hypertens 2014; 32 (6): 1326–33.
21. Musini V, Nazer M, Bassett K, Wright J. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; 29; (5).
22. Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV (опрос пациентов с артериальной гипертонией). Системные гипертензии. 2015; 12 (3): 11–8. / Leonova M.V., Belousov Iu.B., Shteinberg L.L. et al. The results of the pharmacoepidemiological study PIFAGOR IV concerning arterial hypertension (AH patients survey). Systemic Hypertension. 2015; 12 (3): 11–18. [in Russian]
23. Ábrahám G, Dézsi C. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Adv Ther 2017; 34 (7): 1753–63.
24. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs 2014; 14 (2): 137–45.
25. Mourad J, Amodeo C, de Champvallins M et al. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens 2017; 35 (7): 1481–95. DOI: 10.1097/HJH.0000000000001359
26. Chalmers J, Arima H, Woodward M et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014; 63: 259–64.
27. Кобалава Ж.Д., Троицкая Е.А., Толкачева В.В. Комбинированная терапия артериальной гипертонии с использованием трехкомпонентной фиксированной комбинации амлодипина, индапамида и периндоприла аргинина в клинической практике: организация и основные результаты программы ДОКАЗАТЕЛЬСТВО. Кардиология. 2018; 58 (9): 21–30. / Kobalava Zh.D., Troitskaia E.A., Tolkacheva V.V. Kombinirovannaia terapiia arterial'noi gipertonii s ispol'zovaniem trekhkomponentnoi fiksirovannoi kombinatsii amlodipina, indapamida i perindoprila arginina v klinicheskoi praktike: organizatsiia i osnovnye rezul'taty programmy DOKAZATEL'STVO. Kardiologiia. 2018; 58 (9): 21–30. [in Russian]
28. Горбунов В.М. Современные представления о вариабельности артериального давления. Рациональная фармакотерапия в кардиологии. 2012; 8 (6): 810–8. / Gorbunov V.M. Sovremennye predstavleniia o variabel'nosti arterial'nogo davleniia. Ratsional'naia farmakoterapiia v kardiologii. 2012; 8 (6): 810–8. [in Russian]
29. Феськова А.А., Кравченко А.Я. Особенности клинического течения гипертонической болезни на фоне субклинической гипофункции щитовидной железы. Системный анализ и управление в биомедицинских системах. 2015; 14 (3): 473–6. / Fes'kova A.A., Kravchenko A.Ia. Osobennosti klinicheskogo techeniia gipertonicheskoi bolezni na fone subklinicheskoi gipofunktsii shchitovidnoi zhelezy. Sistemnyi analiz i upravlenie v biomeditsinskikh sistemakh. 2015; 14 (3): 473–6. [in Russian]
30. Кравченко А.Я., Черных А.А., Будневский А.В. Вариабельность артерильного давления у больных артериальной гипертензией и избыточной массой тела. Кардиоваск. терапия и профилактика. 2016; 15 (S): 100. / Kravchenko A.Ia., Chernykh A.A., Budnevskii A.V. Variabel'nost' arterial'nogo davleniia u bol'nykh arterial'noi gipertenziei i izbytochnoi massoi tela. Kardiovask. terapiia i profilaktika. 2016; 15 (S): 100. [in Russian]
31. Lalić J., Radovanović R., Mitić B. et al. Medication Adherence in Outpatients with Arterial Hypertension. Sci J Fac Med Niš 2013; 30: 209–18.
2. Chazova I.E. Arterial'naia gipertoniia v svete sovremennykh rekomendatsii. Therapeutic Archive. 2018; 90 (9): 4–7. [in Russian]
3. Forouzanfar M, Liu P, Roth G et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017; 317: 165–82.
4. Меna LJ, Maestre GE, Hansen TW et al. The behalf of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information? Am J Hypertens 2014; 27 (1): 46–55.
5. Mancia G, Fagard R et al. ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014; 23: 3–16.
6. Williams B, Mancia G, Spiering W et al. ESC Scientific Document Group; 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J 2018; 39 (33): 3021–104.
7. Pall D, Szanto L, Szabo Z. Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of treatment with Perindopril, Amlodipine, and Indapamide SR. Clin Drug Investig 2014; 34 (10): 701–8.
8. Ostroumova O.D., Kochetkov A.I., Pavleeva E.E., Guseva T.F. Sovremennye predstavleniia o vybore fiksirovannykh kombinatsii antigipertenzivnykh preparatov: fokus na effektivnost' i prognoz. Lechebnoe delo. 2018; 2: 39–48. [in Russian]
9. Morisky DE, Ang A, Krousel-Wood M, Harry J. Ward. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10 (5): 348–54.
10. Ferreire SA. bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 1965; 24:163–9.
11. Gavras H, Brunner HR, Turini GA et al. Antihypertensive effect of the oral angiotensin convertingenzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298 (18): 991–5.
12. Yang L, Zhang J, Li N et al. Bradykinin receptor in immune-mediated renal tubular injury in trichloroethylene-sensitized mice: Impact on NF-kB signaling pathway. J Immunotoxicol 2018; 15 (1): 126–36.
13. Yousif M, Benter I, Diz D, Chappell M. Angiotensin-(1-7)-dependent vasorelaxation of the renal arteryexhibitsunique angiotensin and bradikinin receptor selektivity. Peptides 2017; 90: 10–6.
14. Gouni-Berthoid Hanssen R, Ravarani L, Berthold H. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. Curr Pharm Des 2017; 23 (31): 4573–82.
15. Jicheng L, Jicheng L, Perkovic V, Foote CV. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012; 12: CD004136.
16. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033–41.
17. Fox K, Henderson J, Bertrand M et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.
18. Dahlof B, Sever P, Poulter N et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
19. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166 (6): 659–66.
20. Parati G, Dolan E, Schumacher H. Impact of antihypertensive combination and monotreatments on blood pressure variability: assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database. J Hypertens 2014; 32 (6): 1326–33.
21. Musini V, Nazer M, Bassett K, Wright J. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; 29; (5).
22. Leonova M.V., Belousov Iu.B., Shteinberg L.L. et al. The results of the pharmacoepidemiological study PIFAGOR IV concerning arterial hypertension (AH patients survey). Systemic Hypertension. 2015; 12 (3): 11–18. [in Russian]
23. Ábrahám G, Dézsi C. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Adv Ther 2017; 34 (7): 1753–63.
24. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs 2014; 14 (2): 137–45.
25. Mourad J, Amodeo C, de Champvallins M et al. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens 2017; 35 (7): 1481–95. DOI: 10.1097/HJH.0000000000001359
26. Chalmers J, Arima H, Woodward M et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014; 63: 259–64.
27. Kobalava Zh.D., Troitskaia E.A., Tolkacheva V.V. Kombinirovannaia terapiia arterial'noi gipertonii s ispol'zovaniem trekhkomponentnoi fiksirovannoi kombinatsii amlodipina, indapamida i perindoprila arginina v klinicheskoi praktike: organizatsiia i osnovnye rezul'taty programmy DOKAZATEL'STVO. Kardiologiia. 2018; 58 (9): 21–30. [in Russian]
28. Gorbunov V.M. Sovremennye predstavleniia o variabel'nosti arterial'nogo davleniia. Ratsional'naia farmakoterapiia v kardiologii. 2012; 8 (6): 810–8. [in Russian]
29. Fes'kova A.A., Kravchenko A.Ia. Osobennosti klinicheskogo techeniia gipertonicheskoi bolezni na fone subklinicheskoi gipofunktsii shchitovidnoi zhelezy. Sistemnyi analiz i upravlenie v biomeditsinskikh sistemakh. 2015; 14 (3): 473–6. [in Russian]
30. Kravchenko A.Ia., Chernykh A.A., Budnevskii A.V. Variabel'nost' arterial'nogo davleniia u bol'nykh arterial'noi gipertenziei i izbytochnoi massoi tela. Kardiovask. terapiia i profilaktika. 2016; 15 (S): 100. [in Russian]
31. Lalić J., Radovanović R., Mitić B. et al. Medication Adherence in Outpatients with Arterial Hypertension. Sci J Fac Med Niš 2013; 30: 209–18.
2. Чазова И.Е. Артериальная гипертония в свете современных рекомендаций. Терапевтический архив. 2018; 90 (9): 4–7. / Chazova I.E. Arterial'naia gipertoniia v svete sovremennykh rekomendatsii. Therapeutic Archive. 2018; 90 (9): 4–7. [in Russian]
3. Forouzanfar M, Liu P, Roth G et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017; 317: 165–82.
4. Меna LJ, Maestre GE, Hansen TW et al. The behalf of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information? Am J Hypertens 2014; 27 (1): 46–55.
5. Mancia G, Fagard R et al. ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014; 23: 3–16.
6. Williams B, Mancia G, Spiering W et al. ESC Scientific Document Group; 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J 2018; 39 (33): 3021–104.
7. Pall D, Szanto L, Szabo Z. Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of treatment with Perindopril, Amlodipine, and Indapamide SR. Clin Drug Investig 2014; 34 (10): 701–8.
8. Остроумова О.Д., Кочетков А.И., Павлеева Е.Е., Гусева Т.Ф. Современные представления о выборе фиксированных комбинаций антигипертензивных препаратов: фокус на эффективность и прогноз. Лечебное дело. 2018; 2: 39–48. / Ostroumova O.D., Kochetkov A.I., Pavleeva E.E., Guseva T.F. Sovremennye predstavleniia o vybore fiksirovannykh kombinatsii antigipertenzivnykh preparatov: fokus na effektivnost' i prognoz. Lechebnoe delo. 2018; 2: 39–48. [in Russian]
9. Morisky DE, Ang A, Krousel-Wood M, Harry J. Ward. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10 (5): 348–54.
10. Ferreire SA. bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 1965; 24:163–9.
11. Gavras H, Brunner HR, Turini GA et al. Antihypertensive effect of the oral angiotensin convertingenzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298 (18): 991–5.
12. Yang L, Zhang J, Li N et al. Bradykinin receptor in immune-mediated renal tubular injury in trichloroethylene-sensitized mice: Impact on NF-kB signaling pathway. J Immunotoxicol 2018; 15 (1): 126–36.
13. Yousif M, Benter I, Diz D, Chappell M. Angiotensin-(1-7)-dependent vasorelaxation of the renal arteryexhibitsunique angiotensin and bradikinin receptor selektivity. Peptides 2017; 90: 10–6.
14. Gouni-Berthoid Hanssen R, Ravarani L, Berthold H. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. Curr Pharm Des 2017; 23 (31): 4573–82.
15. Jicheng L, Jicheng L, Perkovic V, Foote CV. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012; 12: CD004136.
16. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033–41.
17. Fox K, Henderson J, Bertrand M et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.
18. Dahlof B, Sever P, Poulter N et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
19. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166 (6): 659–66.
20. Parati G, Dolan E, Schumacher H. Impact of antihypertensive combination and monotreatments on blood pressure variability: assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database. J Hypertens 2014; 32 (6): 1326–33.
21. Musini V, Nazer M, Bassett K, Wright J. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; 29; (5).
22. Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV (опрос пациентов с артериальной гипертонией). Системные гипертензии. 2015; 12 (3): 11–8. / Leonova M.V., Belousov Iu.B., Shteinberg L.L. et al. The results of the pharmacoepidemiological study PIFAGOR IV concerning arterial hypertension (AH patients survey). Systemic Hypertension. 2015; 12 (3): 11–18. [in Russian]
23. Ábrahám G, Dézsi C. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Adv Ther 2017; 34 (7): 1753–63.
24. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs 2014; 14 (2): 137–45.
25. Mourad J, Amodeo C, de Champvallins M et al. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens 2017; 35 (7): 1481–95. DOI: 10.1097/HJH.0000000000001359
26. Chalmers J, Arima H, Woodward M et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014; 63: 259–64.
27. Кобалава Ж.Д., Троицкая Е.А., Толкачева В.В. Комбинированная терапия артериальной гипертонии с использованием трехкомпонентной фиксированной комбинации амлодипина, индапамида и периндоприла аргинина в клинической практике: организация и основные результаты программы ДОКАЗАТЕЛЬСТВО. Кардиология. 2018; 58 (9): 21–30. / Kobalava Zh.D., Troitskaia E.A., Tolkacheva V.V. Kombinirovannaia terapiia arterial'noi gipertonii s ispol'zovaniem trekhkomponentnoi fiksirovannoi kombinatsii amlodipina, indapamida i perindoprila arginina v klinicheskoi praktike: organizatsiia i osnovnye rezul'taty programmy DOKAZATEL'STVO. Kardiologiia. 2018; 58 (9): 21–30. [in Russian]
28. Горбунов В.М. Современные представления о вариабельности артериального давления. Рациональная фармакотерапия в кардиологии. 2012; 8 (6): 810–8. / Gorbunov V.M. Sovremennye predstavleniia o variabel'nosti arterial'nogo davleniia. Ratsional'naia farmakoterapiia v kardiologii. 2012; 8 (6): 810–8. [in Russian]
29. Феськова А.А., Кравченко А.Я. Особенности клинического течения гипертонической болезни на фоне субклинической гипофункции щитовидной железы. Системный анализ и управление в биомедицинских системах. 2015; 14 (3): 473–6. / Fes'kova A.A., Kravchenko A.Ia. Osobennosti klinicheskogo techeniia gipertonicheskoi bolezni na fone subklinicheskoi gipofunktsii shchitovidnoi zhelezy. Sistemnyi analiz i upravlenie v biomeditsinskikh sistemakh. 2015; 14 (3): 473–6. [in Russian]
30. Кравченко А.Я., Черных А.А., Будневский А.В. Вариабельность артерильного давления у больных артериальной гипертензией и избыточной массой тела. Кардиоваск. терапия и профилактика. 2016; 15 (S): 100. / Kravchenko A.Ia., Chernykh A.A., Budnevskii A.V. Variabel'nost' arterial'nogo davleniia u bol'nykh arterial'noi gipertenziei i izbytochnoi massoi tela. Kardiovask. terapiia i profilaktika. 2016; 15 (S): 100. [in Russian]
31. Lalić J., Radovanović R., Mitić B. et al. Medication Adherence in Outpatients with Arterial Hypertension. Sci J Fac Med Niš 2013; 30: 209–18.
________________________________________________
2. Chazova I.E. Arterial'naia gipertoniia v svete sovremennykh rekomendatsii. Therapeutic Archive. 2018; 90 (9): 4–7. [in Russian]
3. Forouzanfar M, Liu P, Roth G et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017; 317: 165–82.
4. Меna LJ, Maestre GE, Hansen TW et al. The behalf of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information? Am J Hypertens 2014; 27 (1): 46–55.
5. Mancia G, Fagard R et al. ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014; 23: 3–16.
6. Williams B, Mancia G, Spiering W et al. ESC Scientific Document Group; 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J 2018; 39 (33): 3021–104.
7. Pall D, Szanto L, Szabo Z. Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of treatment with Perindopril, Amlodipine, and Indapamide SR. Clin Drug Investig 2014; 34 (10): 701–8.
8. Ostroumova O.D., Kochetkov A.I., Pavleeva E.E., Guseva T.F. Sovremennye predstavleniia o vybore fiksirovannykh kombinatsii antigipertenzivnykh preparatov: fokus na effektivnost' i prognoz. Lechebnoe delo. 2018; 2: 39–48. [in Russian]
9. Morisky DE, Ang A, Krousel-Wood M, Harry J. Ward. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10 (5): 348–54.
10. Ferreire SA. bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 1965; 24:163–9.
11. Gavras H, Brunner HR, Turini GA et al. Antihypertensive effect of the oral angiotensin convertingenzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298 (18): 991–5.
12. Yang L, Zhang J, Li N et al. Bradykinin receptor in immune-mediated renal tubular injury in trichloroethylene-sensitized mice: Impact on NF-kB signaling pathway. J Immunotoxicol 2018; 15 (1): 126–36.
13. Yousif M, Benter I, Diz D, Chappell M. Angiotensin-(1-7)-dependent vasorelaxation of the renal arteryexhibitsunique angiotensin and bradikinin receptor selektivity. Peptides 2017; 90: 10–6.
14. Gouni-Berthoid Hanssen R, Ravarani L, Berthold H. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. Curr Pharm Des 2017; 23 (31): 4573–82.
15. Jicheng L, Jicheng L, Perkovic V, Foote CV. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012; 12: CD004136.
16. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033–41.
17. Fox K, Henderson J, Bertrand M et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782–8.
18. Dahlof B, Sever P, Poulter N et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
19. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166 (6): 659–66.
20. Parati G, Dolan E, Schumacher H. Impact of antihypertensive combination and monotreatments on blood pressure variability: assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database. J Hypertens 2014; 32 (6): 1326–33.
21. Musini V, Nazer M, Bassett K, Wright J. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; 29; (5).
22. Leonova M.V., Belousov Iu.B., Shteinberg L.L. et al. The results of the pharmacoepidemiological study PIFAGOR IV concerning arterial hypertension (AH patients survey). Systemic Hypertension. 2015; 12 (3): 11–18. [in Russian]
23. Ábrahám G, Dézsi C. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Adv Ther 2017; 34 (7): 1753–63.
24. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs 2014; 14 (2): 137–45.
25. Mourad J, Amodeo C, de Champvallins M et al. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens 2017; 35 (7): 1481–95. DOI: 10.1097/HJH.0000000000001359
26. Chalmers J, Arima H, Woodward M et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014; 63: 259–64.
27. Kobalava Zh.D., Troitskaia E.A., Tolkacheva V.V. Kombinirovannaia terapiia arterial'noi gipertonii s ispol'zovaniem trekhkomponentnoi fiksirovannoi kombinatsii amlodipina, indapamida i perindoprila arginina v klinicheskoi praktike: organizatsiia i osnovnye rezul'taty programmy DOKAZATEL'STVO. Kardiologiia. 2018; 58 (9): 21–30. [in Russian]
28. Gorbunov V.M. Sovremennye predstavleniia o variabel'nosti arterial'nogo davleniia. Ratsional'naia farmakoterapiia v kardiologii. 2012; 8 (6): 810–8. [in Russian]
29. Fes'kova A.A., Kravchenko A.Ia. Osobennosti klinicheskogo techeniia gipertonicheskoi bolezni na fone subklinicheskoi gipofunktsii shchitovidnoi zhelezy. Sistemnyi analiz i upravlenie v biomeditsinskikh sistemakh. 2015; 14 (3): 473–6. [in Russian]
30. Kravchenko A.Ia., Chernykh A.A., Budnevskii A.V. Variabel'nost' arterial'nogo davleniia u bol'nykh arterial'noi gipertenziei i izbytochnoi massoi tela. Kardiovask. terapiia i profilaktika. 2016; 15 (S): 100. [in Russian]
31. Lalić J., Radovanović R., Mitić B. et al. Medication Adherence in Outpatients with Arterial Hypertension. Sci J Fac Med Niš 2013; 30: 209–18.
Авторы
В.Н.Ларина*1, Д.А.Орлов1, В.П.Сидорова2
1 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ГБУЗ «Диагностический клинический центр №1» Департамента здравоохранения г. Москвы. 117485, Россия, Москва, ул. Миклухо-Маклая, д. 29, корп. 2
*larinav@mail.ru
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 Diagnostic Center №1 of the Department of Health of Moscow. 117485, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 29, korp. 2
*larinav@mail.ru
1 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ГБУЗ «Диагностический клинический центр №1» Департамента здравоохранения г. Москвы. 117485, Россия, Москва, ул. Миклухо-Маклая, д. 29, корп. 2
*larinav@mail.ru
________________________________________________
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 Diagnostic Center №1 of the Department of Health of Moscow. 117485, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 29, korp. 2
*larinav@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.